Indeed, acquiring the FLT3 mutation during the clonal evolution that characterizes leukemic relapse would make these patients suitable candidates for treatment with an oral, selectively effective FLT3 inhibitor with single-agent activity, such as gilteritinib, in R/R FLT3-mutated AML [39,146,147]. This evidence concerns the gene FLT3 and acute myeloid leukemia.